5-Amino-1MQ
C10H11N2+
159.21 g/mol · PubChem CID 950107
3 selected publications · 0 human intervention studies
Peptides, bioregulators & nootropics
Explore molecular identities, source-provided structures and selected scientific publications. Move from the research record to exact supplier packages, with the evidence and commercial sources clearly identified.
150 catalog profiles · Source check 2026-10-09 · English research edition
150 profiles shown. A linked publication is not a recommendation for use. Human studies, preclinical experiments and reviews are labeled separately.
ACE-031
Molecular identity needs further verification
3 selected publications · 2 human intervention studies · 4 registered trials
Acetyl Hexapeptide-3 (Argireline)
C35H62N14O11S
887.0 g/mol · PubChem CID 71587772
6 selected publications · 1 human intervention study · 3 registered trials
Adalank Spray
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Adamax
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Adamax 1032 Spray
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Adipotide
C111H206N36O28S2
2557.2 g/mol · PubChem CID 163360068
1 selected publication · 0 human intervention studies
Agomelatine Powder
C15H17NO2
243.30 g/mol · PubChem CID 82148
8 selected publications · 5 human intervention studies · 19 registered trials
Small molecule · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
AHK-Cu
Molecular identity needs further verification
1 selected publication · 0 human intervention studies
AICAR
C9H14N4O5
258.23 g/mol · PubChem CID 17513
4 selected publications · 3 human intervention studies · 4 registered trials
Small molecule · highest stage: Phase 3
Andarine (S4)
C19H18F3N3O6
441.4 g/mol · PubChem CID 9824562
5 selected publications · 0 human intervention studies
AOD-9604
C78H123N23O23S2
1815.1 g/mol · PubChem CID 71300630
2 selected publications · 0 human intervention studies
ARA-290
C51H84N16O21
1257.3 g/mol · PubChem CID 91810664
7 selected publications · 3 human intervention studies · 2 registered trials
Protein / peptide · highest stage: Phase 2
B7-33
Molecular identity needs further verification
4 selected publications · 0 human intervention studies
BAM15 Capsules
Molecular identity needs further verification
8 selected publications · 0 human intervention studies
BPC-157
C62H98N16O22
1419.5 g/mol · PubChem CID 9941957
7 selected publications · 1 human intervention study · 3 registered trials
Protein / peptide · highest stage: Phase 1
BPC-157 / KPV Capsules
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
BPC-157 / TB-500
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
BPC-157 / TB-500 / MGF
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
Bronchogen
C18H30N4O9
446.5 g/mol · PubChem CID 11690869
6 selected publications · 0 human intervention studies
Cagrilintide
C194H312N54O59S2
4409 g/mol · PubChem CID 171397054
5 selected publications · 4 human intervention studies · 40 registered trials
Protein / peptide · highest stage: Phase 3
CagriSema
Multiple ingredients · no single molecular formula
5 selected publications · 5 human intervention studies · 29 registered trials
Cardarine
C21H18F3NO3S2
453.5 g/mol · PubChem CID 9803963
8 selected publications · 0 human intervention studies · 3 registered trials
Small molecule · highest stage: Phase 2
Cardiogen
Molecular identity needs further verification
1 selected publication · 0 human intervention studies
Cartalax
C12H19N3O8
333.29 g/mol · PubChem CID 87815447
0 selected publications · 0 human intervention studies
Cartalax / BPC-157 / TB-500
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
Cerebrolysin
Molecular identity needs further verification
7 selected publications · 5 human intervention studies · 40 registered trials
Chonluten
C11H17N3O8
319.27 g/mol · PubChem CID 194641
1 selected publication · 0 human intervention studies
CJC-1295 (DAC)
C165H269N47O46
3647.2 g/mol · PubChem CID 91971820
2 selected publications · 2 human intervention studies · 1 registered trial
CJC-1295 (No DAC)
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
CJC-1295 (No DAC) / GHRP-6
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
CJC-1295 / Ipamorelin Nasal Spray
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
Cortagen
C17H26N4O9
430.4 g/mol · PubChem CID 18439621
5 selected publications · 0 human intervention studies
Decapeptide-12
Molecular identity needs further verification
3 selected publications · 2 human intervention studies
Dermorphin
C40H50N8O10
802.9 g/mol · PubChem CID 5485199
1 selected publication · 1 human intervention study
Dihexa
C27H44N4O5
504.7 g/mol · PubChem CID 129010512
2 selected publications · 0 human intervention studies
DSIP
C35H48N10O15
848.8 g/mol · PubChem CID 68816
5 selected publications · 3 human intervention studies
Protein / peptide · highest stage: Phase 2
Eloralintide
Molecular identity needs further verification
4 selected publications · 3 human intervention studies · 22 registered trials
Enclomiphene
C26H28ClNO
406.0 g/mol · PubChem CID 1548953
5 selected publications · 3 human intervention studies · 22 registered trials
Small molecule · highest stage: Phase 3
Epithalon
C14H22N4O9
390.35 g/mol · PubChem CID 219042
4 selected publications · 1 human intervention study
Fasoracetam Powder
C10H16N2O2
196.25 g/mol · PubChem CID 198695
3 selected publications · 1 human intervention study · 6 registered trials
Small molecule · highest stage: Phase 2
Follistatin 344
Molecular identity needs further verification
4 selected publications · 0 human intervention studies
FOXO4-DRI
C228H388N86O64
5358 g/mol · PubChem CID 167312269
4 selected publications · 0 human intervention studies
GHK Basic (Tripeptide-1)
Molecular identity needs further verification
5 selected publications · 0 human intervention studies
GHK-Cu
C14H23CuN6O4+
402.92 g/mol · PubChem CID 71587328
1 selected publication · 0 human intervention studies · 1 registered trial
GHK-Cu / KPV
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
GHK-Cu / KPV / BPC-157
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
GHRP-2
C45H55N9O6
818.0 g/mol · PubChem CID 6918245
8 selected publications · 2 human intervention studies
Protein / peptide · highest stage: Phase 2
GHRP-6
C46H56N12O6
873.0 g/mol · PubChem CID 4345065
2 selected publications · 1 human intervention study
GLOW
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
GLOW (GHK-Cu / TB4 / BPC-157)
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
Glutathione
C10H17N3O6S
307.33 g/mol · PubChem CID 124886
7 selected publications · 3 human intervention studies · 37 registered trials
Small molecule · highest stage: Phase 3
Gonadorelin
C55H75N17O13
1182.3 g/mol · PubChem CID 638793
9 selected publications · 1 human intervention study · 1 registered trial
US: active ingredient of a discontinued FDA approval · Drugs@FDA
Protein / peptide · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
HCG
Molecular identity needs further verification
4 selected publications · 1 human intervention study · 25 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Hexarelin
C47H58N12O6
887.0 g/mol · PubChem CID 6918297
6 selected publications · 5 human intervention studies
Protein / peptide · highest stage: Phase 2
hGH Fragment 176-191
C80H127N23O24S2
1859.1 g/mol · PubChem CID 172966176
0 selected publications · 0 human intervention studies
Humanin
C119H204N34O32S2
2687.2 g/mol · PubChem CID 16131438
1 selected publication · 0 human intervention studies
IGF-1 DES
Molecular identity needs further verification
5 selected publications · 0 human intervention studies
IGF-1 LR3
Molecular identity needs further verification
2 selected publications · 0 human intervention studies
Ipamorelin
C38H49N9O5
711.9 g/mol · PubChem CID 9831659
3 selected publications · 2 human intervention studies · 2 registered trials
Protein / peptide · highest stage: Phase 2
Ipamorelin / CJC-1295
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
ISRIB Powder
C22H24Cl2N2O4
451.3 g/mol · PubChem CID 1011240
3 selected publications · 0 human intervention studies
Kisspeptin-10
C63H83N17O14
1302.4 g/mol · PubChem CID 25240297
5 selected publications · 3 human intervention studies · 5 registered trials
Protein / peptide · highest stage: Phase 3
KLOW
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
KLOW (GHK-Cu / TB4 / BPC-157 / KPV)
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
KPV
C16H30N4O4
342.43 g/mol · PubChem CID 125672
8 selected publications · 0 human intervention studies
L-Carnitine
C7H15NO3
161.20 g/mol · PubChem CID 10917
8 selected publications · 0 human intervention studies · 40 registered trials
Small molecule · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
LGD-4033
C14H12F6N2O
338.25 g/mol · PubChem CID 44137686
8 selected publications · 1 human intervention study · 1 registered trial
Small molecule · highest stage: Phase 2
Lipopeptide (Biopeptide EL)
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Liraglutide
C172H265N43O51
3751 g/mol · PubChem CID 16134956
7 selected publications · 4 human intervention studies · 33 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Protein / peptide · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
Livagen
C18H31N5O9
461.5 g/mol · PubChem CID 87919683
5 selected publications · 0 human intervention studies
LL-37
C205H340N60O53
4493 g/mol · PubChem CID 16198951
4 selected publications · 0 human intervention studies · 2 registered trials
Matrixyl
C39H75N7O10
802.1 g/mol · PubChem CID 9897237
4 selected publications · 0 human intervention studies
Mazdutide
C207H317N45O65
4476 g/mol · PubChem CID 167312357
7 selected publications · 6 human intervention studies · 40 registered trials
Protein / peptide · highest stage: Phase 3
Melanotan-1
C78H111N21O19
1646.8 g/mol · PubChem CID 16197727
3 selected publications · 2 human intervention studies · 23 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Protein / peptide · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
Melanotan-2
C50H69N15O9
1024.2 g/mol · PubChem CID 92432
3 selected publications · 2 human intervention studies · 1 registered trial
Methylene Blue Solution
C16H18ClN3S
319.9 g/mol · PubChem CID 6099
5 selected publications · 2 human intervention studies · 40 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Small molecule · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
MGF
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
MK-677
C27H36N4O5S
528.7 g/mol · PubChem CID 178024
4 selected publications · 4 human intervention studies · 4 registered trials
Small molecule · highest stage: Phase 2
MK-777 (Acetamoren)
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
MOTS-c
C101H152N28O22S2
2174.6 g/mol · PubChem CID 146675088
6 selected publications · 0 human intervention studies · 1 registered trial
N-Acetyl Epitalon Amidate
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
N-Acetyl Selank
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
N-Acetyl Semax
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
N-Acetyl Semax Amidate
C39H54N10O10S
855.0 g/mol · PubChem CID 172638603
0 selected publications · 0 human intervention studies
NAD+
C21H27N7O14P2
663.4 g/mol · PubChem CID 5892
1 selected publication · 1 human intervention study · 7 registered trials
Small molecule · highest stage: Phase 2
NAD+ / MOTS-c / 5-Amino-1MQ
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
Nefiracetam Powder
C14H18N2O2
246.30 g/mol · PubChem CID 71157
7 selected publications · 3 human intervention studies · 1 registered trial
Small molecule · highest stage: Phase 2
Nonapeptide-1
C61H87N15O9S
1206.5 g/mol · PubChem CID 10418849
1 selected publication · 0 human intervention studies
Noopept Powder
C17H22N2O4
318.4 g/mol · PubChem CID 180496
6 selected publications · 2 human intervention studies
Orforglipron Capsules
C48H48F2N10O5
883.0 g/mol · PubChem CID 137319706
8 selected publications · 6 human intervention studies · 40 registered trials
Small molecule · highest stage: Phase 3
Ostarine
C19H14F3N3O3
389.33 g/mol · ChEMBL CHEMBL1738889
8 selected publications · 0 human intervention studies · 17 registered trials
Small molecule · highest stage: Phase 3
Ovagen
C15H25N3O8
375.37 g/mol · PubChem CID 444128
0 selected publications · 0 human intervention studies
Oxytocin
C43H66N12O12S2
1007.2 g/mol · PubChem CID 439302
8 selected publications · 4 human intervention studies · 36 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Protein / peptide · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
P21
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Pal-AHK
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Pal-GHK
C30H54N6O5
578.8 g/mol · PubChem CID 10231864
0 selected publications · 0 human intervention studies
Pancragen
C26H36N6O9
576.6 g/mol · PubChem CID 68452877
5 selected publications · 0 human intervention studies
PE-22-28
Molecular identity needs further verification
1 selected publication · 0 human intervention studies
PEG MGF
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Pentapeptide-18 (Leuphasyl)
C29H39N5O7
569.6 g/mol · PubChem CID 10099522
2 selected publications · 0 human intervention studies
Phenibut FAA Powder
C10H13NO2
179.22 g/mol · PubChem CID 14113
5 selected publications · 3 human intervention studies
Small molecule · highest stage: Not reported
Phenibut HCl Powder
C10H14ClNO2
215.67 g/mol · PubChem CID 11499499
5 selected publications · 3 human intervention studies
Pinealon
C15H26N6O8
418.40 g/mol · PubChem CID 10273502
6 selected publications · 0 human intervention studies
PNC-27
C188H293N53O44S
4032 g/mol · PubChem CID 16201774
5 selected publications · 0 human intervention studies
PP405
Molecular identity needs further verification
0 selected publications · 0 human intervention studies · 2 registered trials
Pramiracetam Powder
C14H27N3O2
269.38 g/mol · PubChem CID 51712
4 selected publications · 3 human intervention studies · 1 registered trial
Small molecule · highest stage: Phase 2
Prostamax
C20H33N5O9
487.5 g/mol · PubChem CID 9848296
5 selected publications · 0 human intervention studies
PT-141
C50H68N14O10
1025.2 g/mol · PubChem CID 9941379
7 selected publications · 6 human intervention studies · 10 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Protein / peptide · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
PT-141 / Oxytocin Nasal Spray
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
PTD-DBM
Molecular identity needs further verification
3 selected publications · 0 human intervention studies
RAD-140
C20H16ClN5O2
393.8 g/mol · PubChem CID 44200882
8 selected publications · 0 human intervention studies · 1 registered trial
Small molecule · highest stage: Phase 2
RAD-150 (TLB-150)
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Retatrutide
C221H342N46O68
4731 g/mol · PubChem CID 171390338
9 selected publications · 7 human intervention studies · 34 registered trials
Retatrutide / Cagrilintide
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
RU-58841
C17H18F3N3O3
369.34 g/mol · PubChem CID 132981
6 selected publications · 0 human intervention studies
RU-58841 5% / Minoxidil 10% Solution
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
S-23
C18H13ClF4N2O3
416.8 g/mol · PubChem CID 24892822
3 selected publications · 0 human intervention studies
Selank
C33H57N11O9
751.9 g/mol · PubChem CID 11765600
6 selected publications · 3 human intervention studies
Semaglutide
C187H291N45O59
4114 g/mol · PubChem CID 56843331
8 selected publications · 5 human intervention studies · 34 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Protein / peptide · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
Semax
C37H51N9O10S
813.9 g/mol · PubChem CID 9811102
5 selected publications · 4 human intervention studies
Semax / Selank
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
Semax / Selank / Pinealon Spray
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
Sermorelin
C149H246N44O42S
3357.9 g/mol · PubChem CID 16132413
5 selected publications · 2 human intervention studies
US: active ingredient of a discontinued FDA approval · Drugs@FDA
SLU-PP-332
C18H14N2O2
290.3 g/mol · PubChem CID 5338394
3 selected publications · 0 human intervention studies
SNAP-8
C41H70N16O16S
1075.2 g/mol · PubChem CID 76283482
0 selected publications · 0 human intervention studies
SR-9009 (Stenabolic)
C20H24ClN3O4S
437.9 g/mol · PubChem CID 57394020
8 selected publications · 0 human intervention studies
SS-31
C32H49N9O5
639.8 g/mol · PubChem CID 11764719
7 selected publications · 5 human intervention studies · 30 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Protein / peptide · highest stage: Approved (Drugs@FDA)
Survodutide
C192H289N47O61
4232 g/mol · PubChem CID 168429725
6 selected publications · 6 human intervention studies · 27 registered trials
Protein / peptide · highest stage: Phase 3
Syn-AKE
C23H37N5O7
495.6 g/mol · PubChem CID 71465152
1 selected publication · 0 human intervention studies
Syn-Coll
C33H65N5O5
611.9 g/mol · PubChem CID 11950477
0 selected publications · 0 human intervention studies
TB-500
Molecular identity needs further verification
1 selected publication · 0 human intervention studies · 1 registered trial
TB-500 Fragment (17-23)
Molecular identity needs further verification
1 selected publication · 0 human intervention studies · 1 registered trial
Tesamorelin
C221H366N72O67S
5136 g/mol · PubChem CID 16137828
7 selected publications · 7 human intervention studies · 20 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Protein / peptide · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
Tesamorelin / Ipamorelin
Multiple ingredients · no single molecular formula
0 selected publications · 0 human intervention studies
Tesofensine Capsules
C17H23Cl2NO
328.3 g/mol · PubChem CID 11370864
7 selected publications · 5 human intervention studies · 9 registered trials
Small molecule · highest stage: Phase 2
Testagen
Molecular identity needs further verification
2 selected publications · 0 human intervention studies · 1 registered trial
Thymalin
Molecular identity needs further verification
8 selected publications · 5 human intervention studies
Thymogen
C16H19N3O5
333.34 g/mol · PubChem CID 100094
8 selected publications · 5 human intervention studies
Small molecule · highest stage: Phase 3
Thymosin Alpha-1
C129H215N33O55
3108.3 g/mol · PubChem CID 16130571
6 selected publications · 3 human intervention studies · 38 registered trials
Protein / peptide · highest stage: Phase 3
Thymosin Beta-4
C212H350N56O78S
4963 g/mol · PubChem CID 45382195
4 selected publications · 1 human intervention study · 9 registered trials
Tirzepatide
C225H348N48O68
4813 g/mol · PubChem CID 156588324
8 selected publications · 7 human intervention studies · 38 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Protein / peptide · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
TRH (Protirelin)
C16H22N6O4
362.38 g/mol · PubChem CID 638678
8 selected publications · 0 human intervention studies · 6 registered trials
Protein / peptide · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
Tripeptide-29
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Triptorelin
C64H82N18O13
1311.4 g/mol · PubChem CID 25074470
6 selected publications · 2 human intervention studies · 29 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Protein / peptide · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
Vesugen
C15H26N4O8
390.39 g/mol · PubChem CID 87571363
5 selected publications · 0 human intervention studies
Vialox (Pentapeptide-3V)
Molecular identity needs further verification
1 selected publication · 0 human intervention studies
Vilon
C11H21N3O5
275.30 g/mol · PubChem CID 7010502
8 selected publications · 3 human intervention studies
VIP
C147H237N43O43S
3326.8 g/mol · PubChem CID 53314964
5 selected publications · 1 human intervention study · 7 registered trials
YK-11
C25H34O6
430.5 g/mol · PubChem CID 119058028
8 selected publications · 0 human intervention studies
How to read the library
Molecular values describe a specific source record. Salts, counterions, peptide sequences and modifications can change that identity. A 2D diagram is a reference depiction, not an analysis of a vendor batch. When a record is unresolved, we show the gap instead of assigning a similar molecule.
PubMed publication types help organize the selected bibliography; they do not grade study quality or prove a treatment effect. Reviews and encyclopedia articles provide context. The original methods, population, formulation, controls and limitations must be checked before interpreting an experiment.